Evolus's ROE % for the quarter that ended in Dec. 2024 was -476.06%. Evolus's PB Ratio for the quarter that ended in Dec. 2024 was 126.90.
Evolus's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -3.75%.
Evolus ROE % Adjusted to Book Value Historical Data
The historical data trend for Evolus's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Evolus's ROE % Adjusted to Book Value
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Evolus's ROE % Adjusted to Book Value falls into.
Evolus ROE % Adjusted to Book Value Calculation
Evolus's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus ROE % Adjusted to Book Value Related Terms
Thank you for viewing the detailed overview of Evolus's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EOLS has been successfully added to your 